About Us
Kinagen’s mission is to establish a new class of drugs capable of locking targeted kinases in their inactive state, providing more selective, safe and effective drugs for patients with a range of conditions.


Senior Management

David Slack, President & CEO, BOD Member


Rich Canote - Vice President, Finance


Scientific Advisory Board, Consultants & Collaborators

David Cheresh, Ph.D. - Co-founder, BOD Member, SAB Member

Lee Arnold, Ph.D. - SAB Member and Consultant

Homer Pearce, Ph.D. - SAB Member

Peter Farina, Ph.D. - SAB Member

Keith Flaherty, M.D. - SAB Member and Collaborator

Eric Murphy, Ph.D. - Co-founder, Consultant and Collaborator

Wolf Wrasidlo, Ph.D. - Co-founder and Consultant




Kinagen’s team provides leading biology, chemistry, drug discovery, development and business expertise, and has advanced 12 kinase-targeted drugs into clinical development and several to market.

Experience spans leading biotech, pharmaceutical companies and academic institutions including:
  • Abbott Laboratories
  • Altair Therapeutics
  • Aventis Pharma
  • BASF Pharma
  • Boehringer Ingelheim
  • Eli Lilly & Company
  • Harvard / Mass General Cancer Center
  • Isis Pharmaceuticals
  • Moores UCSD Cancer Center
  • OSI Pharmaceuticals
  • Pfizer
  • Scripps Research Institute
  • TargeGen